More patients reach glycaemic control with a fixed ‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - June 14, 2018 Category: Endocrinology Authors: Juan Frias MD , Manuel Puig Domingo MD , Luigi Meneghini MD , Raffaele Napoli MD , Minzhi Liu PhD , Erika Soltes Rak PhD , Vanita R. Aroda MD Source Type: research